Across TCGA pan-cancer cohorts, SLC25A29 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLC25A29 data layer compared with 29 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC25A29 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC25A29 expression acts as an unfavorable survival marker.

BLCA are the cancer types where SLC25A29 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.152	0.625	.012	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: SLC25A29 tumor-vs-normal RNA expression · all SLC25A29 data types